2. Waite, J., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R., Ajithdoss, D., Godin, S., Ramos, I., Wu, Q., Oswald, E., Poon, P., Golubov, J., Grote, D., Stella, J., Pawashe, A., Finney, J., Herlihy, E., Ahmed, H., Kamat, V., Dorvilliers, A., Navarro, E., Xiao, J., Kim, J., Yang, S., Warsaw, J., Lett, C., Canova, L., Schulenburg, T., Foster, R., Krueger, P., Garnova, E., Rafique, A., Babb, R., Chen, G., Oristian, N., Siao, C., Daly, C., Gurer, C., Martin, J., Macdonald, L., MacDonald, D., Poueymirou, W., Smith, E., Lowy, I., Thurston, G., Olson, W., Lin, J., Sleeman, M., Yancopoulos, G., Murphy, A. and Skokos, D.(2020). Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy . Science Translational Medicine 12(549). DOI:
10.1126/scitranslmed.aba2325